Prevention of recurrent hepatitis B infection after liver transplantation
BACKGROUND:Recurrence of hepatitis B virus(HBV) infection after liver transplantation can lead to graft loss and a reduction in long-term survival.The purpose of this review is to summarize the current therapeutic options for preventing HBV recurrence in liver transplant recipients.DATA SOURCES:Up t...
Gespeichert in:
| Veröffentlicht in: | Hepatobiliary & pancreatic diseases international 2013-10, Vol.12 (5), p.465-472 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 472 |
|---|---|
| container_issue | 5 |
| container_start_page | 465 |
| container_title | Hepatobiliary & pancreatic diseases international |
| container_volume | 12 |
| creator | Wong, Tiffany CL Fung, James YY Lo, Chung Mau |
| description | BACKGROUND:Recurrence of hepatitis B virus(HBV) infection after liver transplantation can lead to graft loss and a reduction in long-term survival.The purpose of this review is to summarize the current therapeutic options for preventing HBV recurrence in liver transplant recipients.DATA SOURCES:Up to January 2013,studies that were published in MEDLINE and EMBASE on prevention of HBV recurrence after liver transplantation were reviewed.RESULTS:There have been remarkable advancements in the past two decades on the prevention of HBV recurrence after liver transplantation,from the discovery of hepatitis B immune globulin(HBIG) and lamivudine monotherapy to the combination therapy using HBIG and lamivudine.With the development of newer and stronger antiviral agents,the need for life-long HBIG is doubtful.With their low resistance profile,oral antiviral prophylaxis using these new agents alone is sufficient and is associated with excellent outcome.CONCLUSIONS:Restoration of host HBV immunity with adoptive immunity transfer and vaccination may represent the ultimate strategy to withdraw prophylactic treatment and to achieve a drug free regimen against HBV recurrence after liver transplantation. |
| doi_str_mv | 10.1016/S1499-3872(13)60074-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443396063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>1003034436</cqvip_id><els_id>1_s2_0_S1499387213600740</els_id><sourcerecordid>1443396063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-c1cbde6ff456fe8d9375660f9c68be419fd89228d123a628cd8f3ca88678f9303</originalsourceid><addsrcrecordid>eNqFkM1OGzEUhb2gIhR4hFYjsYHFFP-Nx7NpBajQSEggQdeW47kG04knsT2R8vb1JAEhNmxs-fr4HJ8PoW8E_yCYiPMHwpumZLKmp4SdCYxrXuI9dPA2nqCvMb5gTKWsxD6aUE4wo3V1gKb3AVbgk-t90dsigBlCyOfiGRY6ueRicVk4b8FsJNomCEXnVnlNQfu46LRPerw7Ql-s7iIc7_ZD9Pf69-PVn_L27mZ6dXFbGs5lKg0xsxaEtbwSFmTbsLoSAtvGCDkDThrbyoZS2RLKtKDStNIyo6UUtbQNw-wQnW59F6FfDhCTmrtooMsfgX6IinDOWCOwYFlabaUm9DEGsGoR3FyHtSJYjeTUhpwaESnC1IacGiO-7yKG2Rzat1ev2LLg11YAuejKQVDROPAGWpcJJtX27tOInx8cTOe8M7r7B2uIL_0QfKaoiIpU4a3J6EHYxmE0ONl1e-7909L5p3flcOaUMQj2H-IHoJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1443396063</pqid></control><display><type>article</type><title>Prevention of recurrent hepatitis B infection after liver transplantation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><creator>Wong, Tiffany CL ; Fung, James YY ; Lo, Chung Mau</creator><creatorcontrib>Wong, Tiffany CL ; Fung, James YY ; Lo, Chung Mau</creatorcontrib><description>BACKGROUND:Recurrence of hepatitis B virus(HBV) infection after liver transplantation can lead to graft loss and a reduction in long-term survival.The purpose of this review is to summarize the current therapeutic options for preventing HBV recurrence in liver transplant recipients.DATA SOURCES:Up to January 2013,studies that were published in MEDLINE and EMBASE on prevention of HBV recurrence after liver transplantation were reviewed.RESULTS:There have been remarkable advancements in the past two decades on the prevention of HBV recurrence after liver transplantation,from the discovery of hepatitis B immune globulin(HBIG) and lamivudine monotherapy to the combination therapy using HBIG and lamivudine.With the development of newer and stronger antiviral agents,the need for life-long HBIG is doubtful.With their low resistance profile,oral antiviral prophylaxis using these new agents alone is sufficient and is associated with excellent outcome.CONCLUSIONS:Restoration of host HBV immunity with adoptive immunity transfer and vaccination may represent the ultimate strategy to withdraw prophylactic treatment and to achieve a drug free regimen against HBV recurrence after liver transplantation.</description><identifier>ISSN: 1499-3872</identifier><identifier>DOI: 10.1016/S1499-3872(13)60074-0</identifier><identifier>PMID: 24103275</identifier><language>eng</language><publisher>Singapore: Elsevier B.V</publisher><subject>Adaptive Immunity ; Administration, Oral ; adoptive ; adoptive immunity transfer ; Adoptive Transfer ; antiviral ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; antiviral therapy ; Drug Administration Schedule ; Drug Resistance, Viral ; Endocrinology & Metabolism ; Gastroenterology and Hepatology ; globulin ; HBV ; HBV vaccination ; hepatitis ; hepatitis B ; Hepatitis B - diagnosis ; Hepatitis B - immunology ; Hepatitis B - prevention & control ; hepatitis B immune globulin ; Hepatitis B Vaccines - therapeutic use ; Hepatitis B virus - drug effects ; Hepatitis B virus - growth & development ; Hepatitis B virus - immunology ; Humans ; immune ; immunity ; Immunoglobulins - therapeutic use ; Lamivudine - therapeutic use ; liver ; liver transplantation ; Liver Transplantation - adverse effects ; Secondary Prevention ; therapy ; transfer ; transplantation ; Treatment Outcome ; vaccination ; Virus Activation - drug effects</subject><ispartof>Hepatobiliary & pancreatic diseases international, 2013-10, Vol.12 (5), p.465-472</ispartof><rights>The Editorial Board of Hepatobiliary & Pancreatic Diseases International</rights><rights>2013 The Editorial Board of Hepatobiliary & Pancreatic Diseases International</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-c1cbde6ff456fe8d9375660f9c68be419fd89228d123a628cd8f3ca88678f9303</citedby><cites>FETCH-LOGICAL-c448t-c1cbde6ff456fe8d9375660f9c68be419fd89228d123a628cd8f3ca88678f9303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/89801X/89801X.jpg</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1499-3872(13)60074-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24103275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Tiffany CL</creatorcontrib><creatorcontrib>Fung, James YY</creatorcontrib><creatorcontrib>Lo, Chung Mau</creatorcontrib><title>Prevention of recurrent hepatitis B infection after liver transplantation</title><title>Hepatobiliary & pancreatic diseases international</title><addtitle>Hepatobiliary & Pancreatic Diseases International</addtitle><description>BACKGROUND:Recurrence of hepatitis B virus(HBV) infection after liver transplantation can lead to graft loss and a reduction in long-term survival.The purpose of this review is to summarize the current therapeutic options for preventing HBV recurrence in liver transplant recipients.DATA SOURCES:Up to January 2013,studies that were published in MEDLINE and EMBASE on prevention of HBV recurrence after liver transplantation were reviewed.RESULTS:There have been remarkable advancements in the past two decades on the prevention of HBV recurrence after liver transplantation,from the discovery of hepatitis B immune globulin(HBIG) and lamivudine monotherapy to the combination therapy using HBIG and lamivudine.With the development of newer and stronger antiviral agents,the need for life-long HBIG is doubtful.With their low resistance profile,oral antiviral prophylaxis using these new agents alone is sufficient and is associated with excellent outcome.CONCLUSIONS:Restoration of host HBV immunity with adoptive immunity transfer and vaccination may represent the ultimate strategy to withdraw prophylactic treatment and to achieve a drug free regimen against HBV recurrence after liver transplantation.</description><subject>Adaptive Immunity</subject><subject>Administration, Oral</subject><subject>adoptive</subject><subject>adoptive immunity transfer</subject><subject>Adoptive Transfer</subject><subject>antiviral</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral therapy</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Viral</subject><subject>Endocrinology & Metabolism</subject><subject>Gastroenterology and Hepatology</subject><subject>globulin</subject><subject>HBV</subject><subject>HBV vaccination</subject><subject>hepatitis</subject><subject>hepatitis B</subject><subject>Hepatitis B - diagnosis</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - prevention & control</subject><subject>hepatitis B immune globulin</subject><subject>Hepatitis B Vaccines - therapeutic use</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - growth & development</subject><subject>Hepatitis B virus - immunology</subject><subject>Humans</subject><subject>immune</subject><subject>immunity</subject><subject>Immunoglobulins - therapeutic use</subject><subject>Lamivudine - therapeutic use</subject><subject>liver</subject><subject>liver transplantation</subject><subject>Liver Transplantation - adverse effects</subject><subject>Secondary Prevention</subject><subject>therapy</subject><subject>transfer</subject><subject>transplantation</subject><subject>Treatment Outcome</subject><subject>vaccination</subject><subject>Virus Activation - drug effects</subject><issn>1499-3872</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1OGzEUhb2gIhR4hFYjsYHFFP-Nx7NpBajQSEggQdeW47kG04knsT2R8vb1JAEhNmxs-fr4HJ8PoW8E_yCYiPMHwpumZLKmp4SdCYxrXuI9dPA2nqCvMb5gTKWsxD6aUE4wo3V1gKb3AVbgk-t90dsigBlCyOfiGRY6ueRicVk4b8FsJNomCEXnVnlNQfu46LRPerw7Ql-s7iIc7_ZD9Pf69-PVn_L27mZ6dXFbGs5lKg0xsxaEtbwSFmTbsLoSAtvGCDkDThrbyoZS2RLKtKDStNIyo6UUtbQNw-wQnW59F6FfDhCTmrtooMsfgX6IinDOWCOwYFlabaUm9DEGsGoR3FyHtSJYjeTUhpwaESnC1IacGiO-7yKG2Rzat1ev2LLg11YAuejKQVDROPAGWpcJJtX27tOInx8cTOe8M7r7B2uIL_0QfKaoiIpU4a3J6EHYxmE0ONl1e-7909L5p3flcOaUMQj2H-IHoJg</recordid><startdate>201310</startdate><enddate>201310</enddate><creator>Wong, Tiffany CL</creator><creator>Fung, James YY</creator><creator>Lo, Chung Mau</creator><general>Elsevier B.V</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201310</creationdate><title>Prevention of recurrent hepatitis B infection after liver transplantation</title><author>Wong, Tiffany CL ; Fung, James YY ; Lo, Chung Mau</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-c1cbde6ff456fe8d9375660f9c68be419fd89228d123a628cd8f3ca88678f9303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adaptive Immunity</topic><topic>Administration, Oral</topic><topic>adoptive</topic><topic>adoptive immunity transfer</topic><topic>Adoptive Transfer</topic><topic>antiviral</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral therapy</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Viral</topic><topic>Endocrinology & Metabolism</topic><topic>Gastroenterology and Hepatology</topic><topic>globulin</topic><topic>HBV</topic><topic>HBV vaccination</topic><topic>hepatitis</topic><topic>hepatitis B</topic><topic>Hepatitis B - diagnosis</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - prevention & control</topic><topic>hepatitis B immune globulin</topic><topic>Hepatitis B Vaccines - therapeutic use</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - growth & development</topic><topic>Hepatitis B virus - immunology</topic><topic>Humans</topic><topic>immune</topic><topic>immunity</topic><topic>Immunoglobulins - therapeutic use</topic><topic>Lamivudine - therapeutic use</topic><topic>liver</topic><topic>liver transplantation</topic><topic>Liver Transplantation - adverse effects</topic><topic>Secondary Prevention</topic><topic>therapy</topic><topic>transfer</topic><topic>transplantation</topic><topic>Treatment Outcome</topic><topic>vaccination</topic><topic>Virus Activation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Tiffany CL</creatorcontrib><creatorcontrib>Fung, James YY</creatorcontrib><creatorcontrib>Lo, Chung Mau</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatobiliary & pancreatic diseases international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Tiffany CL</au><au>Fung, James YY</au><au>Lo, Chung Mau</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of recurrent hepatitis B infection after liver transplantation</atitle><jtitle>Hepatobiliary & pancreatic diseases international</jtitle><addtitle>Hepatobiliary & Pancreatic Diseases International</addtitle><date>2013-10</date><risdate>2013</risdate><volume>12</volume><issue>5</issue><spage>465</spage><epage>472</epage><pages>465-472</pages><issn>1499-3872</issn><abstract>BACKGROUND:Recurrence of hepatitis B virus(HBV) infection after liver transplantation can lead to graft loss and a reduction in long-term survival.The purpose of this review is to summarize the current therapeutic options for preventing HBV recurrence in liver transplant recipients.DATA SOURCES:Up to January 2013,studies that were published in MEDLINE and EMBASE on prevention of HBV recurrence after liver transplantation were reviewed.RESULTS:There have been remarkable advancements in the past two decades on the prevention of HBV recurrence after liver transplantation,from the discovery of hepatitis B immune globulin(HBIG) and lamivudine monotherapy to the combination therapy using HBIG and lamivudine.With the development of newer and stronger antiviral agents,the need for life-long HBIG is doubtful.With their low resistance profile,oral antiviral prophylaxis using these new agents alone is sufficient and is associated with excellent outcome.CONCLUSIONS:Restoration of host HBV immunity with adoptive immunity transfer and vaccination may represent the ultimate strategy to withdraw prophylactic treatment and to achieve a drug free regimen against HBV recurrence after liver transplantation.</abstract><cop>Singapore</cop><pub>Elsevier B.V</pub><pmid>24103275</pmid><doi>10.1016/S1499-3872(13)60074-0</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1499-3872 |
| ispartof | Hepatobiliary & pancreatic diseases international, 2013-10, Vol.12 (5), p.465-472 |
| issn | 1499-3872 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1443396063 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier) |
| subjects | Adaptive Immunity Administration, Oral adoptive adoptive immunity transfer Adoptive Transfer antiviral Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use antiviral therapy Drug Administration Schedule Drug Resistance, Viral Endocrinology & Metabolism Gastroenterology and Hepatology globulin HBV HBV vaccination hepatitis hepatitis B Hepatitis B - diagnosis Hepatitis B - immunology Hepatitis B - prevention & control hepatitis B immune globulin Hepatitis B Vaccines - therapeutic use Hepatitis B virus - drug effects Hepatitis B virus - growth & development Hepatitis B virus - immunology Humans immune immunity Immunoglobulins - therapeutic use Lamivudine - therapeutic use liver liver transplantation Liver Transplantation - adverse effects Secondary Prevention therapy transfer transplantation Treatment Outcome vaccination Virus Activation - drug effects |
| title | Prevention of recurrent hepatitis B infection after liver transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T03%3A25%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20recurrent%20hepatitis%20B%20infection%20after%20liver%20transplantation&rft.jtitle=Hepatobiliary%20&%20pancreatic%20diseases%20international&rft.au=Wong,%20Tiffany%20CL&rft.date=2013-10&rft.volume=12&rft.issue=5&rft.spage=465&rft.epage=472&rft.pages=465-472&rft.issn=1499-3872&rft_id=info:doi/10.1016/S1499-3872(13)60074-0&rft_dat=%3Cproquest_cross%3E1443396063%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1443396063&rft_id=info:pmid/24103275&rft_cqvip_id=1003034436&rft_els_id=1_s2_0_S1499387213600740&rfr_iscdi=true |